重藥控股(000950.SZ):控股子公司應收賬款2期資產支持專項計劃成功設立
格隆匯1月21日丨重藥控股(000950.SZ)公佈,2021年1月20日,公司收到招商財富轉發的《招商財富-重慶醫藥應收賬款2期資產支持專項計劃成立公吿》。招商財富-重慶醫藥應收賬款2期資產支持專項計劃的管理人招商財富資產管理有限公司已向合格投資者發行優先級與次級資產支持證券,並得到全額認購,其中部分次級資產支持證券由重慶醫藥(集團)股份有限公司認購。專項計劃於2021年1月20日正式設立,該專項計劃資產支持證券總規模6億元,德勤華永會計師事務所(特殊普通合夥)進行驗資並出具《招商財富-重慶醫藥應收賬款2期資產支持專項計劃驗資報吿》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.